Type 1 metabotropic glutamate receptor and its signaling molecules as therapeutic targets for the treatment of cerebellar disorders

Curr Opin Pharmacol. 2018 Feb;38:51-58. doi: 10.1016/j.coph.2018.02.002. Epub 2018 Mar 8.

Abstract

Neurodegenerative diseases such as spinocerebellar ataxias and autoantibody-associated disorders of the central nervous system often affect the cerebellum, resulting in motor deficits. Recent studies have revealed that most of these disorders impair type 1 metabotropic glutamate receptor (mGluR1) and/or the closely associated signaling molecules in cerebellar Purkinje cell. Since the signaling pathway triggered by mGluR1 activation in Purkinje cell plays a pivotal role in coordinated movements and motor learning, pharmacological repair of aberrant mGluR1 signaling in Purkinje cell is critical for mitigation of cerebellar symptoms. Here we review recently identified pathophysiology underlying the neurodegenerative and autoimmune diseases affecting mGluR1 signaling in Purkinje cell and possible therapeutic interventions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cerebellar Diseases / drug therapy
  • Cerebellar Diseases / metabolism*
  • Humans
  • Purkinje Cells / metabolism*
  • Receptors, Metabotropic Glutamate / metabolism*
  • Signal Transduction

Substances

  • Receptors, Metabotropic Glutamate
  • metabotropic glutamate receptor type 1